174 related articles for article (PubMed ID: 33818626)
21. Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy naïve patients with suspicious prostate cancer.
Nowier A; Mazhar H; Salah R; Shabayek M
Arab J Urol; 2022; 20(3):121-125. PubMed ID: 35935910
[TBL] [Abstract][Full Text] [Related]
22. Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.
Prabhu V; Rosenkrantz AB; Otazo R; Sodickson DK; Kang SK
J Magn Reson Imaging; 2019 May; 49(5):1400-1408. PubMed ID: 30629317
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of clinically significant prostate cancer using biparametric magnetic resonance imaging: An evolving concept.
Mahajan M; Gupta V; Gupta P; Sharma P; Abrol D
J Cancer Res Ther; 2022; 18(6):1640-1645. PubMed ID: 36412424
[TBL] [Abstract][Full Text] [Related]
24. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
25. Quantitative assessment of dynamic
Tau N; Berlin A; Yeung I; Halankar J; Murphy G; Jhaveri KS; Ghai S; Metser U
Br J Radiol; 2019 Feb; 92(1094):20180568. PubMed ID: 30383459
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
[No Abstract] [Full Text] [Related]
27. PI-RADS v2 and ADC values: is there room for improvement?
Jordan EJ; Fiske C; Zagoria R; Westphalen AC
Abdom Radiol (NY); 2018 Nov; 43(11):3109-3116. PubMed ID: 29550953
[TBL] [Abstract][Full Text] [Related]
28. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
29. T1 Mapping of the Prostate Using Single-Shot T1FLASH: A Clinical Feasibility Study to Optimize Prostate Cancer Assessment.
Al-Bourini O; Seif Amir Hosseini A; Giganti F; Balz J; Heitz LG; Voit D; Lotz J; Trojan L; Frahm J; Uhlig A; Uhlig J
Invest Radiol; 2023 Jun; 58(6):380-387. PubMed ID: 36729865
[TBL] [Abstract][Full Text] [Related]
30. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
Felker ER; Raman SS; Margolis DJ; Lu DSK; Shaheen N; Natarajan S; Sharma D; Huang J; Dorey F; Marks LS
AJR Am J Roentgenol; 2017 Dec; 209(6):1272-1277. PubMed ID: 28858541
[TBL] [Abstract][Full Text] [Related]
31. Luminal Water Imaging: Comparison With Diffusion-Weighted Imaging (DWI) and PI-RADS for Characterization of Prostate Cancer Aggressiveness.
Hectors SJ; Said D; Gnerre J; Tewari A; Taouli B
J Magn Reson Imaging; 2020 Jul; 52(1):271-279. PubMed ID: 31961049
[TBL] [Abstract][Full Text] [Related]
32. Value of T
Klingebiel M; Schimmöller L; Weiland E; Franiel T; Jannusch K; Kirchner J; Hilbert T; Strecker R; Arsov C; Wittsack HJ; Albers P; Antoch G; Ullrich T
J Magn Reson Imaging; 2022 Aug; 56(2):413-422. PubMed ID: 35038203
[TBL] [Abstract][Full Text] [Related]
33. Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2.
Greer MD; Shih JH; Lay N; Barrett T; Kayat Bittencourt L; Borofsky S; Kabakus IM; Law YM; Marko J; Shebel H; Mertan FV; Merino MJ; Wood BJ; Pinto PA; Summers RM; Choyke PL; Turkbey B
Radiology; 2017 Dec; 285(3):859-869. PubMed ID: 28727501
[TBL] [Abstract][Full Text] [Related]
34. Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization.
Cristel G; Esposito A; Damascelli A; Briganti A; Ambrosi A; Brembilla G; Brunetti L; Antunes S; Freschi M; Montorsi F; Del Maschio A; De Cobelli F
Eur J Radiol; 2019 Sep; 118():51-57. PubMed ID: 31439258
[TBL] [Abstract][Full Text] [Related]
35. Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
Othman AE; Falkner F; Weiss J; Kruck S; Grimm R; Martirosian P; Nikolaou K; Notohamiprodjo M
Invest Radiol; 2016 May; 51(5):290-6. PubMed ID: 26619282
[TBL] [Abstract][Full Text] [Related]
36. Multiparametric magnetic resonance imaging - Transrectal ultrasound-guided cognitive fusion biopsy of the prostate: Clinically significant cancer detection rates stratified by the Prostate Imaging and Data Reporting System version 2 assessment category.
John S; Cooper S; Breau RH; Flood TA; Cagiannos I; Lavallee LT; Morash C; O'sullivan J; Schieda N
Can Urol Assoc J; 2018 Dec; 12(12):401-406. PubMed ID: 29940139
[TBL] [Abstract][Full Text] [Related]
37. Comparison of different population-averaged arterial-input-functions in dynamic contrast-enhanced MRI of the prostate: Effects on pharmacokinetic parameters and their diagnostic performance.
Othman AE; Falkner F; Kessler DE; Martirosian P; Weiss J; Kruck S; Kaufmann S; Grimm R; Kramer U; Nikolaou K; Notohamiprodjo M
Magn Reson Imaging; 2016 May; 34(4):496-501. PubMed ID: 26708031
[TBL] [Abstract][Full Text] [Related]
38. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
39. A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness.
Baur ADJ; Schwabe J; Rogasch J; Maxeiner A; Penzkofer T; Stephan C; Rudl M; Hamm B; Jung EM; Fischer T
Eur Radiol; 2018 May; 28(5):1949-1960. PubMed ID: 29238867
[TBL] [Abstract][Full Text] [Related]
40. How Often is the Dynamic Contrast Enhanced Score Needed in PI-RADS Version 2?
Roh AT; Fan RE; Sonn GA; Vasanawala SS; Ghanouni P; Loening AM
Curr Probl Diagn Radiol; 2020; 49(3):173-176. PubMed ID: 31126664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
